|
|
Upfront Briefing
July opens with the checkbook out and the risk dial turned up: Ipsen is buying Memo Therapeutics for a rare-disease antibody that quietly whiffed its primary endpoint, Canada just cleared the first generic Wegovy in a G7 market, and Boulevard is renting a preclinical China T-cell engager for $20M down and $1.6B in promises.
Translation: buyers are paying for secondaries, Novo's moat has its first real leak, and "bio-bucks" is still doing a lot of heavy lifting on a molecule that hasn't named its targets. Same dealmaking machine, higher degree of difficulty.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,499.4 |
0.8% |
9.3% |
| Nasdaq 100 |
30,276.3 |
1.7% |
20.1% |
| Russell 2000 |
3,024.4 |
0.5% |
20.6% |
| Healthcare (XLV) |
158.7 |
(1.3%) |
2.0% |
| Biotech (XBI) |
158.2 |
0.0% |
30.2% |
| Nasdaq Biotech (NBI) |
6,564.9 |
0.0% |
15.0% |
| Clinical Trials (BBC) |
52.7 |
0.3% |
40.0% |
|
- Healthcare gave ground into quarter-end even as dealmaking held up — XLV fell 1.3% while XBI finished flat, with Ipsen's move on Memo Therapeutics and a 10-plus-name FDA July calendar framing the sector's next catalysts.
- The broad tape closed its strongest quarter since 2020 on AI and semiconductor leadership; quarter-end positioning and a Mag7 rebound carried the Nasdaq 100 past the S&P 500.
- Market data: U.S. cash close Tuesday, 30 June 2026.
The Big 3
|
1
|
Ipsen to acquire Memo Therapeutics for BK-virus antibody potravitug
|
-
Ipsen signed a definitive share purchase agreement to acquire all of Memo Therapeutics AG, adding potravitug, a Phase II antibody for BK polyomavirus nephropathy (BKPyVAN) in kidney-transplant patients with FDA Fast Track and EU orphan status. Terms undisclosed; close targeted for Q3 2026.
-
Why it matters: Ipsen is buying into a niche with no approved targeted therapy — BKPyV can reactivate in up to half of transplant recipients and drive graft loss. But the nuance the release soft-pedals: SAFE KIDNEY II (n=95, 22 U.S. sites) missed its primary endpoint of undetectable BKPyV DNAemia. Ipsen is paying on the secondary — biopsy-proven nephropathy fell to 31.6% at week 20 from 51.2% at baseline, versus no change on placebo, plus a ≥1-log viral-load response. Fast Track and EU orphan trim timelines, but this de-risks at the pivotal Phase II/III, not today.
-
Source:
Ipsen
-
More:
Memo Therapeutics
|
|
2
|
Health Canada clears first generic Wegovy for weight loss
|
-
Apotex won Health Canada approval for Svemia (marketed as SEVMIA), the first generic semaglutide cleared for chronic weight management in a G7 market — a generic of Novo Nordisk's Wegovy. It's Canada's third generic semaglutide, but the first for obesity rather than diabetes.
-
Why it matters: The read-through runs straight at Novo. Canadian generics run 45–90% below brand, and Health Canada says six more semaglutide submissions are queued. Novo's U.S. cliff (2032+) still buffers its biggest market, but Canada — where compound protection lapsed early — is now a live case study in how fast branded GLP-1 volume erodes once copies land, and a preview of the pricing gravity the whole obesity complex faces. Apotex, fresh off a ~$1.5B IPO (TSX: APTX), gets an obesity foothold to build on.
-
Source:
BioSpace
-
More:
Health Canada
|
|
3
|
Boulevard strikes $1.6B pact for China trispecific T-cell engager
|
-
U.S.-based, Deerfield-backed Boulevard Bio licensed global rights to Metis TechBio's MTS-128, a preclinical trispecific T-cell engager for autoimmune disease — $20M upfront, up to $1.6B in development, regulatory and commercial milestones, plus tiered royalties.
-
Why it matters: The price tag is a bio-bucks headline — $20M actually changes hands now; the other $1.6B is milestone paper on a preclinical asset that hasn't even named its three targets. What's real is the theme: T-cell engagers aimed at autoimmune disease are this year's hot modality, validated by Cullinan's lupus data and Astellas' $1.7B Vir pact, and Boulevard is licensing a trispecific twist on it. The catch is sourcing — MTS-128 is another China-discovered asset, carrying the same COINS Act overhang stalking Pfizer/Innovent-type deals. Preclinical means years to any data inflection; call it a low-cost bet on the modality, not a de-risked one.
-
Source:
Fierce Biotech
|
Everything Else that broke
- Kowa filed a U.S. NDA for Nicox’s NCX 470, triggering a €3M milestone payment. — PR
- Hanmi closed its C$2.41/share (28% premium) acquisition of AML-focused Aptose Biosciences; Aptose delists from the TSX around July 3. — GlobeNewswire
- Vistagen's intranasal fasedienol missed primary and secondary endpoints in the 238-patient PALISADE-4 Phase 3 in social anxiety; shares fell 70% to $0.23 as it pitches the FDA a single-trial path off a post hoc subgroup. — Fierce Biotech
- FDA pushed Praxis' relutrigine decision three months to Dec. 27, classing added sensitivity analyses as a major amendment; TD Cowen tied the slip to agency bandwidth. — Fierce Biotech
- FDA gene-therapy chief Vijay Kumar is stepping down as acting head of CBER's Office of Therapeutic Products; acting CBER director Karim Mikhail takes interim oversight. — Fierce Biotech
- Bain- and RA Capital-backed Angitia scrapped lead BMP-6 asset AGA111, halting a Phase 3 spinal-fusion trial (not safety-driven) to focus on two Phase 2 bone bispecifics. — Fierce Biotech
- FDA's July calendar carries at least 10 decision dates, including a cell therapy pushed from April — a dense catalyst month landing as the agency sheds review leadership. — BioCentury
- WuXi AppTec is seeking an injunction to remove its Chinese military designation. — BioCentury
- Santhera highlighted topline Phase 1 AGAMREE data from Catalyst’s study. — PR
- Congress’ China trial consent probe appears thinly backed, according to BioCentury. — BioCentury
- Anthropic said it will begin developing its own drugs. — STAT
- MindMaze enrolled first patients in SwissNeuroRehab to support at-home reimbursement in Europe. — PR
- Abivax rebounded 38% to $132.89 after fresh obefazimod maintenance safety data reframed its earlier cancer-case scare, ahead of a planned Q4 UC filing. — Fierce Biotech
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Ipsen is acquiring Memo Therapeutics for potravitug, a Phase II BKPyVAN antibody (see The Big 3). — Ipsen
- Hanmi completed its C$2.41/share acquisition of Aptose Biosciences (see Everything Else). — GlobeNewswire
- Boulevard Bio licensed a trispecific TCE (MTS-128) from China's Metis TechBio — $20M upfront, up to $1.6B milestones (see The Big 3). — Fierce Biotech
- Eurobio finalized its acquisition of CareDx's transplant Lab Products division. — PR
- PharmaResearch plans to acquire CG USA to expand REJURAN in the Americas. — PR
VC / Private Financings
- Beeline Medicines added a $126.3M Series A extension led by existing backers Bain Capital, CPPIB and BMS for its BMS-sourced autoimmune portfolio; lead oral TLR7/8 inhibitor afimetoran has Ph2 lupus data due this year. — Fierce Biotech
IPOs / Follow-Ons
- Abivax launched an ADS public offering and later halted ordinary-share trading in Paris. — PR
Academic Corner - Multi-antigen-targeting T cells were generally well tolerated in pediatric CNS tumors, with one complete response and three long-term responders. — Nature Medicine
- A case-grounded AI agent showed high concordance with hematology tumor board decisions. — Nature Medicine
- Nature Biotech profiled Trogenix’s synthetic super-enhancer platform for cell-specific gene therapy in solid tumors. — Nature Biotech
- Prime editing advanced precise genome engineering and fungal metabolism modulation in filamentous fungi. — Nature Biotech
|
Ipsen's buying a virus problem, Canada's cloning Wegovy, and the FDA's got a July to-do list longer than ours. See you tomorrow. — BioBucks Team
|
|
|
